Loading
Life sciences · Journal article
Translational Oncology · October 20, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Methionine sulfoxide reductase B3 (MSRB3) possesses potent antioxidant activity and is highly expressed in various cancers, often correlating with poor prognosis. However, its biological effect and clinical importance in gastric cancer (GC) remain elusive. In this study, we first validated the expression and prognostic value of MSRB3 in GC through bioinformatics analyzes and clinical specimens. Subsequently, a series of functional experiments in vitro and in vivo were executed to explore the effect of MSRB3 in regulating GC cell proliferation, invasion, migration, ferroptosis, and the tumor immune microenvironment, as well as the underlying mechanisms. Finally, a subcutaneous xenograft model was established to assess the influence of MSRB3 on tumor growth and the efficacy of anti-PD-1 therapy. MSRB3 was markedly elevated in GC, and linked to poor patient prognosis. Functionally, MSRB3 facilitated the growth, migration, and invasion of GC cells. Indeed, MSRB3 stabilized GPX4 protein by inhibiting its ubiquitin-proteasomal-degradation, thereby suppressing lipid peroxidation and ferroptosis, which sustained GC cell survival and malignant progression. In vivo experiments confirmed that MSRB3 promoted tumor growth by inhibiting ferroptosis. Moreover, loss of MSRB3 increased intratumoral CD8⁺ T-cell accumulation and significantly enhanced the therapeutic response to PD-1 blockade. This synergy was reversed via the ferroptosis inhibitor Ferrostatin-1. MSRB3 functions as a suppressor of ferroptosis in GC by preserving GPX4 protein stability. MSRB3 drives tumor progression and confers immunotherapy resistance by stabilizing GPX4 to inhibit ferroptosis. Therefore, targeting MSRB3 may represent a potential strategy to improve immunotherapeutic efficacy in GC.